Literature DB >> 213192

Pancytopenia induced by aminoglutethimide in the treatment of breast cancer.

B Lawrence, R J Santen, A Lipton, H A Harvey, R Hamilton, T Mercurio.   

Abstract

Aminoglutethimide is an investigational agent of proven benefit in the treatment of metastatic breast carcinoma. We report herein a case of aminoglutethimide-induced pancytopenia complicated by bleeding and gram-negative septicemia. Severe pancytopenia is a rare but important side effect of this new drug and is rapidly reversible when the agent is withdrawn.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 213192

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

Review 1.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

2.  Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer.

Authors:  M D Vincent; H M Clink; R C Coombes; I E Smith; R Kandler; T J Powles
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

3.  Aminoglutethimide-induced myelosuppression.

Authors:  J T van der Heijden; T A Splinter
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

Review 4.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

5.  Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach.

Authors:  S Kvinnsland; O Dahl
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

6.  Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies.

Authors:  A L Harris; G Hughes; A J Barrett; S Abusrewil; M Dowsett; I E Smith
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.